Financials data is unavailable for this security.
View more
Year on year Ionis Pharmaceuticals Inc had net income fall 35.80% from a loss of 269.72m to a larger loss of 366.29m despite a 34.10% increase in revenues from 587.37m to 787.65m. An increase in the selling, general and administrative costs as a percentage of sales from 25.59% to 26.99% was a component in the falling net income despite rising revenues.
| Gross margin | 98.70% |
|---|---|
| Net profit margin | -44.68% |
| Operating margin | -46.12% |
| Return on assets | -11.93% |
|---|---|
| Return on equity | -73.38% |
| Return on investment | -13.52% |
More ▼
Cash flow in USDView more
In 2023, Ionis Pharmaceuticals Inc increased its cash reserves by 44.41%, or 122.79m. Cash Flow from Financing totalled 644.08m or 81.77% of revenues. In addition the company used 307.51m for operations while cash used for investing totalled 214.13m.
| Cash flow per share | -2.37 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.20 |
|---|---|
| Tangible book value per share | 4.20 |
More ▼
Balance sheet in USDView more
| Current ratio | 8.91 |
|---|---|
| Quick ratio | 8.82 |
| Total debt/total equity | 1.93 |
|---|---|
| Total debt/total capital | 0.6587 |
More ▼
Growth rates in USD
SmartText is unavailable
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 14.65 |
